<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03706365</url>
  </required_header>
  <id_info>
    <org_study_id>16598</org_study_id>
    <secondary_id>I3Y-MC-JPCM</secondary_id>
    <secondary_id>2016-004276-21</secondary_id>
    <nct_id>NCT03706365</nct_id>
  </id_info>
  <brief_title>A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer</brief_title>
  <acronym>CYCLONE 2</acronym>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to see how safe and effective abemaciclib is when given together
      with abiraterone acetate plus prednisone in participants with metastatic castration resistant
      prostate cancer. Prednisolone may be used instead of prednisone per local regulation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2018</start_date>
  <completion_date type="Anticipated">February 14, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic Progression Free Survival (rPFS)</measure>
    <time_frame>Baseline to Radiographic Disease Progression or Death from Any Cause (Estimated up to 21 Months)</time_frame>
    <description>rPFS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Prostate-Specific Antigen (PSA) Progression</measure>
    <time_frame>Baseline to the Date of the First Observation of PSA Progression (Estimated up to 21 Months)</time_frame>
    <description>Time to PSA progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR): Percentage of Participants with a Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline to Radiographic Disease Progression (Estimated up to 21 Months)</time_frame>
    <description>ORR: Percentage of participants with a CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Date of First Documented CR or PR to Date of Radiographic Disease Progression or Death from Any Cause (Estimated up to 21 Months)</time_frame>
    <description>DOR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to Date of Death Due to Any Cause (Estimated up to 40 Months)</time_frame>
    <description>OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Symptomatic Progression</measure>
    <time_frame>Baseline to the Date of the First Documented Symptomatic Progression (Estimated up to 21 Months)</time_frame>
    <description>Time to symptomatic progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Mean Steady State Exposure of Abemaciclib</measure>
    <time_frame>Postdose Cycle 1 Day 1 through Postdose Cycle 3 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: Mean steady state exposure of abemaciclib</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN2839567</measure>
    <time_frame>Postdose Cycle 1 Day 1 through Postdose Cycle 3 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: Mean steady state exposure of abemaciclib metabolite LSN2839567</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Mean Steady State Exposure of Abemaciclib Metabolite LSN3106726</measure>
    <time_frame>Postdose Cycle 1 Day 1 through Postdose Cycle 3 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: Mean steady state exposure of abemaciclib metabolite LSN3106726</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Mean Steady State Exposure of Abiraterone Acetate</measure>
    <time_frame>Postdose Cycle 1 Day 1 through Postdose Cycle 3 Day 1 (28 Day Cycles)</time_frame>
    <description>PK: Mean Steady State Exposure of Abiraterone Acetate</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>A1. Abiraterone plus Prednisone and Abemaciclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abiraterone plus prednisone administered orally and abemaciclib administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2. Abiraterone plus Prednisone and Abemaciclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abiraterone plus prednisone administered orally and abemaciclib administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1. Abiraterone plus Prednisone and Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Abiraterone plus prednisone administered orally and placebo administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2. Abiraterone plus Prednisone and Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Abiraterone plus prednisone administered orally and placebo administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A. Abiraterone plus Prednisone and Abemaciclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abiraterone plus prednisone administered orally and abemaciclib administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B. Abiraterone plus Prednisone and Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Abiraterone plus prednisone administered orally and placebo administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>A. Abiraterone plus Prednisone and Abemaciclib</arm_group_label>
    <arm_group_label>A1. Abiraterone plus Prednisone and Abemaciclib</arm_group_label>
    <arm_group_label>A2. Abiraterone plus Prednisone and Abemaciclib</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone Acetate</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>A. Abiraterone plus Prednisone and Abemaciclib</arm_group_label>
    <arm_group_label>A1. Abiraterone plus Prednisone and Abemaciclib</arm_group_label>
    <arm_group_label>A2. Abiraterone plus Prednisone and Abemaciclib</arm_group_label>
    <arm_group_label>B. Abiraterone plus Prednisone and Placebo</arm_group_label>
    <arm_group_label>B1. Abiraterone plus Prednisone and Placebo</arm_group_label>
    <arm_group_label>B2. Abiraterone plus Prednisone and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>A. Abiraterone plus Prednisone and Abemaciclib</arm_group_label>
    <arm_group_label>A1. Abiraterone plus Prednisone and Abemaciclib</arm_group_label>
    <arm_group_label>A2. Abiraterone plus Prednisone and Abemaciclib</arm_group_label>
    <arm_group_label>B. Abiraterone plus Prednisone and Placebo</arm_group_label>
    <arm_group_label>B1. Abiraterone plus Prednisone and Placebo</arm_group_label>
    <arm_group_label>B2. Abiraterone plus Prednisone and Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>B. Abiraterone plus Prednisone and Placebo</arm_group_label>
    <arm_group_label>B1. Abiraterone plus Prednisone and Placebo</arm_group_label>
    <arm_group_label>B2. Abiraterone plus Prednisone and Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate.

          -  Metastatic prostate cancer documented by positive bone scan and/or measurable soft
             tissue metastatic lesions by CT or magnetic resonance imaging (MRI).

          -  Progressive disease at study entry demonstrated during continuous androgen-deprivation
             therapy (ADT)/post orchiectomy defined as one or more of the following:

               -  PSA progression

               -  Radiographic progression per Response Evaluation Criteria in Solid Tumors
                  (RECIST)1.1 for soft tissue and/or per Prostate Cancer Working Group 3 (PCWG3)
                  for bone, with or without PSA progression

          -  Be able and willing to undergo mandatory tumor biopsy of at least one metastatic site.

          -  Have adequate organ function.

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.

        Exclusion Criteria:

          -  Prior therapy with cytochrome P450 (CYP)17 inhibitors.

          -  Prior treatment with abemaciclib or any cyclin-dependent kinase (CDK) 4 &amp; 6
             inhibitors.

          -  Prior cytotoxic chemotherapy for metastatic castration resistant prostate cancer
             (participants treated with docetaxel in the metastatic hormone-sensitive prostate
             cancer [mHSPC] are eligible), prior radiopharmaceuticals for prostate cancer, or prior
             enzalutamide, apalutamide, darolutamide or sipuleucel-T. Participants who had prior
             radiation or surgery to all target lesions.

          -  Currently enrolled in a clinical study involving an investigational product.

          -  Gastrointestinal disorder affecting the absorption or ability to swallow large pills.

          -  Clinically significant heart disease, active or chronic liver disease, moderate/severe
             hepatic impairment (Child-Pugh Class B and C).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>clinicaltrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>602-827-2680</phone>
    </contact>
    <investigator>
      <last_name>Jue Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4803422000</phone>
    </contact>
    <investigator>
      <last_name>Alan Haruo Bryce</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>520-626-0082</phone>
    </contact>
    <investigator>
      <last_name>Alejandro Recio Boiles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Bernards Medical Center</name>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <zip>72401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>870-207-8177</phone>
    </contact>
    <investigator>
      <last_name>Mazen Khalil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Blood and Cancer Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>6618627158</phone>
    </contact>
    <investigator>
      <last_name>David Eduardo Kanamori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Healthcare</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92935</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-446-5810</phone>
    </contact>
    <investigator>
      <last_name>Sanjay Sharma</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-534-7600</phone>
    </contact>
    <investigator>
      <last_name>Rana McKay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>310-829-5471</phone>
    </contact>
    <investigator>
      <last_name>Alexandra Drakaki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TRIO - Translational Research in Oncology-US, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>310-794-6500</phone>
    </contact>
    <investigator>
      <last_name>SMO TRIO -Translational Research</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Care</name>
      <address>
        <city>Monterey</city>
        <state>California</state>
        <zip>93940</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8313754105</phone>
    </contact>
    <investigator>
      <last_name>Michael Zachary Koontz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ridley- Tree Cancer Center</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8058790643</phone>
    </contact>
    <investigator>
      <last_name>Julian Reed Davis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>303-388-4876</phone>
    </contact>
    <investigator>
      <last_name>Robert Jotte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>203-200-4822</phone>
    </contact>
    <investigator>
      <last_name>Daniel P. Petrylak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Millennium Oncology</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>954-450-1808</phone>
    </contact>
    <investigator>
      <last_name>Isaac Levy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Center of Brevard</name>
      <address>
        <city>Palm Bay</city>
        <state>Florida</state>
        <zip>32909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>321-725-8300</phone>
    </contact>
    <investigator>
      <last_name>Pavan Kancharla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Treasure Coast</name>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <zip>34952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>772-408-5159</phone>
    </contact>
    <investigator>
      <last_name>Paul M Swanson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Hospital Cancer Institute</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>770-590-8311</phone>
    </contact>
    <investigator>
      <last_name>Crain Garrot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology &amp; Hematology, Inc.</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>260-484-8830</phone>
    </contact>
    <investigator>
      <last_name>Ahad A Sadiq</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A.</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>301-424-6231</phone>
    </contact>
    <investigator>
      <last_name>John M Wallmark</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-726-2943</phone>
    </contact>
    <investigator>
      <last_name>Matthew Smith</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southcoast Centers for Cancer Care</name>
      <address>
        <city>Fairhaven</city>
        <state>Massachusetts</state>
        <zip>02179</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>508-973-7888</phone>
    </contact>
    <investigator>
      <last_name>Sonia Seng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>612-301-2180</phone>
    </contact>
    <investigator>
      <last_name>Arpit Rao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>63142</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>816-276-4000</phone>
    </contact>
    <investigator>
      <last_name>Peter J Van Veldhuizen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>702-952-2140</phone>
    </contact>
    <investigator>
      <last_name>Brian D Vicuna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>518-262-6696</phone>
    </contact>
    <investigator>
      <last_name>David R Shaffer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Medical Professionals of NY</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>315-478-4185</phone>
    </contact>
    <investigator>
      <last_name>Christopher Pieczonka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma Cancer Specialists &amp; Research Institute, LLC</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>918-505-3200</phone>
    </contact>
    <investigator>
      <last_name>Mark R Olsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists PC</name>
      <address>
        <city>Tigard</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>971-708-7600</phone>
    </contact>
    <investigator>
      <last_name>Anthony Pham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>865-544-9773</phone>
    </contact>
    <investigator>
      <last_name>Antony Charles</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-329-7274</phone>
    </contact>
    <investigator>
      <last_name>SMO Sarah Cannon Research Inst.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southwestern Medical Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>214-648-4180</phone>
    </contact>
    <investigator>
      <last_name>Kevin Courtney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>817-850-2011</phone>
    </contact>
    <investigator>
      <last_name>Stephen L Richey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Memorial City</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>281-392-2757</phone>
    </contact>
    <investigator>
      <last_name>Gurjyot K Doshi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Longview Cancer Center</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>903-757-2122</phone>
    </contact>
    <investigator>
      <last_name>Lijo John</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital &amp; Clinic</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>254-724-5918</phone>
    </contact>
    <investigator>
      <last_name>Sherronda M Henderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>US Oncology</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>281-863-1000</phone>
    </contact>
    <investigator>
      <last_name>SMO US Oncology</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Cancer Care and Research Center</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>254-399-0741</phone>
    </contact>
    <investigator>
      <last_name>Carl Chakmakjian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah School of Medicine</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>801-213-5658</phone>
    </contact>
    <investigator>
      <last_name>Neeraj Agarwal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>802-444-0000</phone>
    </contact>
    <investigator>
      <last_name>Steven Ades</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61285140149</phone>
    </contact>
    <investigator>
      <last_name>Lisa Horvath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Southside Cancer Care Centre</name>
      <address>
        <city>Kogarah</city>
        <state>New South Wales</state>
        <zip>2228</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61287385180</phone>
    </contact>
    <investigator>
      <last_name>Paul De Souza</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Macquarie University Hospital</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61298123526</phone>
    </contact>
    <investigator>
      <last_name>Howard Gurney</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61293825105</phone>
    </contact>
    <investigator>
      <last_name>Elizabeth Hovey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Vincents Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61392883167</phone>
    </contact>
    <investigator>
      <last_name>ANTHONY DOWLING</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Finsen Institute</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4535458315</phone>
    </contact>
    <investigator>
      <last_name>Gedske Daugaard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Næstved Sygehus</name>
      <address>
        <city>Næstved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4556512000</phone>
    </contact>
    <investigator>
      <last_name>Redas Trepiakas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Studienpraxis Urologie</name>
      <address>
        <city>Nürtingen</city>
        <state>Baden-Württemberg</state>
        <zip>72622</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>491703809223</phone>
    </contact>
    <investigator>
      <last_name>Susan Feyerabend</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>492518347447</phone>
    </contact>
    <investigator>
      <last_name>Martin Bögemann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4970712986613</phone>
    </contact>
    <investigator>
      <last_name>Arnulf Stenzl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>82234101767</phone>
    </contact>
    <investigator>
      <last_name>Se Hoon Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>82220724035</phone>
    </contact>
    <investigator>
      <last_name>Miso Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>82222288138</phone>
    </contact>
    <investigator>
      <last_name>Sang Joon Shin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>82230105977</phone>
    </contact>
    <investigator>
      <last_name>Jae Lyun Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>31243657657</phone>
    </contact>
    <investigator>
      <last_name>Hendrik Vergunst</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <state>South Holland</state>
        <zip>3015 GD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>31107040704</phone>
    </contact>
    <investigator>
      <last_name>Ronald de Wit</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis, locatie Nieuwegein</name>
      <address>
        <city>Utrecht</city>
        <zip>3543 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>31883204705</phone>
    </contact>
    <investigator>
      <last_name>Maartje Los</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Puerto Rico Hematology/Oncology Group</name>
      <address>
        <city>Bayamon</city>
        <zip>00961</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>7877868088</phone>
    </contact>
    <investigator>
      <last_name>Robert F Hunter Mellado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrul de Oncologie Sf. Nectarie SRL</name>
      <address>
        <city>Craiova</city>
        <state>Dolj</state>
        <zip>200347</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>40351401336</phone>
    </contact>
    <investigator>
      <last_name>Michael Schenker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>S.C. R.T.C. Radiology Therapeutic Center S.R.L.</name>
      <address>
        <city>Otopeni</city>
        <state>Ilfov</state>
        <zip>075100</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>40372744344</phone>
    </contact>
    <investigator>
      <last_name>Elena Ciubotaru</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SC Gral Medical SRL</name>
      <address>
        <city>Bucuresti</city>
        <zip>031422</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>40213230000</phone>
    </contact>
    <investigator>
      <last_name>Cristina Tiut</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic Judetean de Urgenta Sf.Apostol Andrei Constanta</name>
      <address>
        <city>Constanta</city>
        <zip>900591</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>40241662222</phone>
    </contact>
    <investigator>
      <last_name>Laura Mazilu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34951032508</phone>
    </contact>
    <investigator>
      <last_name>Alvaro Montesa Pino</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34932607744</phone>
    </contact>
    <investigator>
      <last_name>José María Piulats Rodríguez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34934893846</phone>
    </contact>
    <investigator>
      <last_name>Joan Carles Galcerán</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34934536561</phone>
    </contact>
    <investigator>
      <last_name>Begoña Mellado</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34914269070</phone>
    </contact>
    <investigator>
      <last_name>Jose Ángel Arranz Arija</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34913368263</phone>
    </contact>
    <investigator>
      <last_name>Teresa Alonso Gordoa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34913908000</phone>
    </contact>
    <investigator>
      <last_name>Guillermo de Velasco Oria de Rueda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Derriford Hospital</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>441752430138</phone>
    </contact>
    <investigator>
      <last_name>Peter Sankey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College Hospital - London</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>442034479088</phone>
    </contact>
    <investigator>
      <last_name>Ursula McGovern</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charing Cross Hospital</name>
      <address>
        <city>Chelsea</city>
        <state>London</state>
        <zip>W6 8RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>442033111419</phone>
    </contact>
    <investigator>
      <last_name>Naveed Sarwar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northampton General Hospital</name>
      <address>
        <city>Northampton</city>
        <zip>NN1 5BD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>442032195200</phone>
    </contact>
    <investigator>
      <last_name>Mario Uccello</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/prostate-cancer/JPCM</url>
    <description>This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>October 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2018</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Castration Resistant Prostate Cancer</keyword>
  <keyword>mCRPC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

